During this symposium, we will consider the myriad social determinants of health in general and – focusing on migraine specifically – critique the current state of diversity in clinical studies. We will also review what the latest data tell us about the efficacy and tolerability of monoclonal antibodies targeting the calcitonin gene-related peptide pathway (CGRP mAbs) for migraine prevention across diverse patient subgroups, including different ethnicities, migraine characteristics and comorbidities.
We hope you will join us as we attempt to address this important question: are we making progress towards a more inclusive, diverse, and equitable global migraine landscape?